Recent Updates
Recently added Catalysts
QURE Negative Sentiment Score: 25/100

UNIQURE N.V. (QURE) INVESTOR ALERT Investors With Large Losses in uniQure N.V. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Key Takeaway: A shareholder lawsuit has been filed against uniQure N.V. alleging that the company misrepresented information regarding AMT-130, a drug intended for Huntington's Disease treatment. The class action concerns investors who purchased shares between September 24 and October 31, 2025. Those impacted have the opportunity to lead the class with a filing deadline of April 13, 2026. Legal representation is contingent upon no upfront fees, highlighting the serious allegations raised by the plaintiffs.

Market Sentiment Analysis

CONCERNS & RISKS

  • A shareholder has filed a securities class action lawsuit against uniQure N.V. due to alleged misrepresentations.
  • The lawsuit claims the company misled investors regarding the drug AMT-130 for Huntington's Disease.
  • Investors with large losses are being encouraged to seek representation, indicating significant financial impact.

Full Press Release Details

NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the ordinary shares of uniQure N.V. (“uniQure” or the “Company”) (NASDAQ: QURE) between September 24, 2025 and October 31, 2025, inclusive.
For more information, submit a form at uniQure N.V. Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@bernlieb.com, or call us at (212) 951-2030.
If you wish to serve as lead plaintiff for the Class, you must file papers by April 13, 2026. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
According to the lawsuit, Defendants made misrepresentations concerning AMT-130, a drug the Company was developing for treatment of Huntington’s Disease.
About Bernstein Liebhard:
Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.
ATTORNEY ADVERTISING. © 2026 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Investor Relations Manager
Bernstein Liebhard LLP

Tags

uniqure class action

Frequently Asked Questions

What is the current class action lawsuit about?

The lawsuit involves misrepresentations by uniQure concerning their drug AMT-130.

Who can participate in the class action lawsuit?

Investors who purchased uniQure shares between September 24 and October 31, 2025, can join.

What is required to be a lead plaintiff?

To be a lead plaintiff, you must file papers by April 13, 2026.

Is there a fee for participating in the lawsuit?

No, all representation is on a contingency fee basis; shareholders pay no fees.

How can I contact Bernstein Liebhard LLP for more details?

You can email Peter Allocco at pallocco@bernlieb.com or call (212) 951-2030.

Last updated: Feb 12, 2026